Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib.
HCC
biomarker
cytokine angiogenic factors
lenvatinib
relative dose intensity
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
10
2019
accepted:
13
03
2020
entrez:
18
6
2020
pubmed:
18
6
2020
medline:
18
6
2020
Statut:
epublish
Résumé
Although lenvatinib was recently approved for treatment of advanced unresectable hepatocellular carcinoma (HCC) based on the phase III REFLECT trial, no biomarkers for management of lenvatinib treatment have been established. The aim of this study is to identify predictive biomarkers for the management of lenvatinib treatment in advanced HCC patients. A total of 41 patients with advanced HCC were enrolled in this retrospective study. Serum levels of 22 circulating cytokines and angiogenic factors (CAFs) were measured by multiplex Luminex assay. Profiles of CAFs, clinical chemistry/hematology parameters, and clinical background were evaluated to explore biomarkers associated with clinical outcomes. Relative dose intensity (RDI) decreased significantly between weeks 1-2 and 3-4 ( This study demonstrates that RDI is an important predictive factor for longer PFS during lenvatinib treatment. In this hypothesis-generating exploratory analysis, we report that a CAF-signature associated with adverse events and RDI could predict PFS, which might contribute to improved management of lenvatinib treatment in HCC patients.
Sections du résumé
BACKGROUND
BACKGROUND
Although lenvatinib was recently approved for treatment of advanced unresectable hepatocellular carcinoma (HCC) based on the phase III REFLECT trial, no biomarkers for management of lenvatinib treatment have been established. The aim of this study is to identify predictive biomarkers for the management of lenvatinib treatment in advanced HCC patients.
METHODS
METHODS
A total of 41 patients with advanced HCC were enrolled in this retrospective study. Serum levels of 22 circulating cytokines and angiogenic factors (CAFs) were measured by multiplex Luminex assay. Profiles of CAFs, clinical chemistry/hematology parameters, and clinical background were evaluated to explore biomarkers associated with clinical outcomes.
RESULTS
RESULTS
Relative dose intensity (RDI) decreased significantly between weeks 1-2 and 3-4 (
CONCLUSION
CONCLUSIONS
This study demonstrates that RDI is an important predictive factor for longer PFS during lenvatinib treatment. In this hypothesis-generating exploratory analysis, we report that a CAF-signature associated with adverse events and RDI could predict PFS, which might contribute to improved management of lenvatinib treatment in HCC patients.
Identifiants
pubmed: 32547646
doi: 10.1177/1758835920922051
pii: 10.1177_1758835920922051
pmc: PMC7249573
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835920922051Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: Kazuaki Chayama has received research funding from Eizai. The funder had no role in the design of the study, collection, analysis, interpretation of data, writing of the manuscript or decision to publish the results.
Références
Anticancer Res. 2019 Sep;39(9):5149-5156
pubmed: 31519627
Nat Med. 2018 Dec;24(12):1845-1851
pubmed: 30397353
Trends Cardiovasc Med. 2008 Jan;18(1):6-14
pubmed: 18206803
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Curr Mol Med. 2003 Sep;3(6):491-508
pubmed: 14527081
N Engl J Med. 2015 Feb 12;372(7):621-30
pubmed: 25671254
Cancers (Basel). 2019 Oct 09;11(10):
pubmed: 31601010
Liver Int. 2017 Feb;37(2):280-289
pubmed: 27501075
J Gastroenterol. 2017 Apr;52(4):512-519
pubmed: 27704266
Toxicol Appl Pharmacol. 2013 Jan 15;266(2):317-27
pubmed: 23164664
Annu Rev Pathol. 2016 May 23;11:251-81
pubmed: 26907525
Cell Rep. 2014 Aug 7;8(3):696-706
pubmed: 25088418
BMC Cancer. 2017 Dec 19;17(1):870
pubmed: 29258450
PLoS One. 2010 Nov 23;5(11):e15543
pubmed: 21124904
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Hepatol Res. 2020 Mar;50(3):382-395
pubmed: 31760660
Lancet Oncol. 2015 Nov;16(15):1473-1482
pubmed: 26482279
Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):461-467
pubmed: 29557694
Biochem Biophys Res Commun. 2018 Dec 9;507(1-4):330-336
pubmed: 30446226
Liver Cancer. 2018 Mar;7(1):1-19
pubmed: 29662829
Lancet. 2017 Sep 16;390(10100):1151-1210
pubmed: 28919116
Liver Cancer. 2017 Jun;6(3):204-215
pubmed: 28626732
Oncol Lett. 2019 Mar;17(3):2583-2591
pubmed: 30854033
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Cancers (Basel). 2019 Jul 04;11(7):
pubmed: 31277479
World J Gastroenterol. 2019 Feb 21;25(7):789-807
pubmed: 30809080
Clin Chim Acta. 2018 Oct;485:158-165
pubmed: 29966621
Eur J Cancer. 2017 Apr;75:213-221
pubmed: 28237867
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Oncogene. 2019 Apr;38(15):2814-2829
pubmed: 30546090
Hepatology. 2019 Aug;70(2):745-747
pubmed: 30802985
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Lancet Oncol. 2012 Oct;13(10):1055-62
pubmed: 22959186
Mol Cancer. 2019 Mar 30;18(1):60
pubmed: 30925919
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Mol Hum Reprod. 2004 Jun;10(6):393-8
pubmed: 15073283
J Gastroenterol Hepatol. 2018 Oct;33(10):1780-1786
pubmed: 29645345
J Cancer. 2019 Apr 21;10(8):1896-1901
pubmed: 31205547